source
- Kailera's oral GLP-1 pill shows ~10% weight loss in Chinese Phase 3 trialKailera Therapeutics reported that its oral GLP-1 candidate HRS-7535 achieved about 10% average weight loss over 44 weeks in a Phase 3 study in China. The highest daily dose led to a mean 9.8% red…
- STAT newsletter highlights the decline of employer-based health insurance in the U.S.John Wilkerson, a Washington correspondent for STAT, writes the D.C. Diagnosis newsletter that focuses on health policy. In this edition he turns his attention to the weakening of the employer-base…